Pharmacy-Led Management of Atrial Fibrillation: Improving Treatment Adherence and Patient Outcomes

References

• United Nations Population Division. World Population Prospects; 2022. Available from: https://data.worldbank.org/indicator/SP.DYN.LE00.IN. Accessed January 10, 2024.
   Google Scholar
• Roser M, Ortiz-Ospina E, Ritchie H Life Expectancy. OurWorldInData.org; 2019. Available from: https://ourworldindata.org/life-expectancy. Accessed January 10, 2024.
   Google Scholar
• United Nations, Department of Economic and Social Affairs, Population Division (2020). World Population Ageing (ST/ESA/SER.A/444); 2019. Available from: https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf. Accessed January 10, 2024.
   Google Scholar
• Department of Health. Long Term Conditions Compendium of Information 3rd edition; 2012. Availabel from: https://assets.publishing.service.gov.uk/media/5a7c638340f0b62aff6c154e/dh_134486.pdf. Accessed January 10, 2024.
   Google Scholar
• United Nations. In: session S-F, ed, A/RES/75/131 United Nations< Decade of Health Ageing (2021–2030); Resolution/Adopted by the General Assembly on 13 December 2020. New York: UN; 2020. Available from: https://cdn.who.int/media/docs/default-source/decade-of-healthy-ageing/decade-proposal-final-apr2020-en.pdf. Accessed January 10, 2024.
   Google Scholar
• World Health Organization. United Nation’s Decade of Healthy Ageing (2021–2030). Geneva: World Health Organization; 2020. Available from: https://www.who.int/initiatives/decade-of-healthy-ageing. Accessed January 10, 2024.
   Google Scholar
• Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43. doi:10.1016/S0140-6736(12)60240-2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Noncommunicable diseases; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases#:~:text=Noncommunicable%20diseases%20(NCDs)%20kill%2041,%2D%20and%20middle%2Dincome%20countries. Accessed January 10, 2024.
   Google Scholar
• Centers for Disease Control and Prevention. Health and Economic Cost and Chronic Diseases. Available from: https://www.cdc.gov/chronicdisease/about/costs/index.htm. Accessed February 26, 2024.
   Google Scholar
• Sabate E Adherence to long-term therapies: evidence for action 2003. Geneva, Switzerland: World Health Organization; 2003. Available from: http://www.who.int/chronic_conditions/adherencereport/en/. Accessed July 15, 2024.
   Google Scholar
• DiMatteo MP, Giordani PJ, Lepper HS, Croghan W. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811. doi:10.1097/00005650-200209000-00009
   PubMed Web of Science ®Google Scholar
• Bryson CL, Au DH, Young B, McDonell MB, Fihn SD. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care. 2007;45(6):497–504. doi:10.1097/MLR.0b013e3180329368
   PubMed Web of Science ®Google Scholar
• Wu JR, Moser DK, de Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J. 2009;157(2):285–291. doi:10.1016/j.ahj.2008.10.001
   PubMed Web of Science ®Google Scholar
• Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health outcomes in ageing populations: a systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85(11):2464–2478. doi:10.1111/bcp.14075
   PubMed Web of Science ®Google Scholar
• Strandberg LR. Drugs as a reason for nursing home admissions. J Am Health Care Assoc. 1984;10:2023.
   Google Scholar
• Luga AO, McGuire MJ. Adherence and health care costs. Risk Manag Health Policy. 2014;7:22–44. doi:10.2147/RMHP.S19801
   Google Scholar
• Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982
   PubMed Web of Science ®Google Scholar
• European Patients Forum. Adherence and concordance EDF position paper; 2015. Available from: https://www.eu-patient.eu/globalassets/policy/adherence-compliance-concordance/adherence-paper-final-rev_external.pdf. Accessed February 26, 2024.
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(3):487–497. doi:10.1056/NEJMra050100
   PubMedGoogle Scholar
• Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–771. doi:10.1016/S0149-2918(98)80139-2
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Prescriptions Dispensed in the Community – statistics for England, 2007–2017. NHS Digital; 2018. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-The-community/prescriptions-dispensed-in-The-community-england---2007---2017#. Accessed February 26, 2024.
   Google Scholar
• Barber N, Parsons K, Clifford S, Darracott R, Horne R. Patients’ problems with new medication for chronic conditions. BMJ Qual Saf. 2004;13(3):172–175. doi:10.1136/qshc.2003.005926
   Google Scholar
• Mukhtar O, Weinman J, Jackson SHD. Intentional non-adherence to medications by older adults. Drugs Ageing. 2014;31(3):149–157. doi:10.1007/s40266-014-0153-9
   PubMed Web of Science ®Google Scholar
• Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Baker DW, Parker RM, Williams MV, Clark WS, Health Literacy and the risk of hospital admission. J Gen Intern Med. 1998;13(12):791–798. doi:10.1046/j.1525-1497.1998.00242.x
   PubMed Web of Science ®Google Scholar
• Ryan AA. Medication compliance and older people: a review of the literature. Int J Nurs Stud. 1999;36(2):153–162. doi:10.1016/S0020-7489(99)00003-6
   PubMed Web of Science ®Google Scholar
• Nielsen-Bohlman L, Panzer AM, Kindig D Health Literacy: a Prescription to End Confusion. Washington, DC: Institute of Medicine of the National Academies; 2004. Available from: https://nap.nationalacademies.org/catalog/10883/health-literacy-a-prescription-to-end-confusion. Accessed February 26, 2024.
   Google Scholar
• Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding Patients’ Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: a Meta-Analytic Review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.0080633
   PubMed Web of Science ®Google Scholar
• Helier MK, Chapman SC, Horne R. Beliefs about medication predict the misattribution of a common symptom as a medication side effect – evidence from an analogue online study. J Psycho Res. 2015;79(6):519–529. doi:10.1016/j.jpsychores.2015.10.003
   Google Scholar
• Shelis E, Tillett W, James D, et al. Changing Medication-related Beliefs: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Health Psychol. 2023;43(3):155–170.
   PubMed Web of Science ®Google Scholar
• Linn AJ, van Weert JCM, Gebevehu BG, et al. Patients’ online information-seeking behaviour throughout treatment: the impact on medication beliefs and medication adherence. Health Communication. 2019;34(12):1461–1468. doi:10.1080/10410236.2018.1500430
   PubMed Web of Science ®Google Scholar
• Al Khaja KAJ, AlKhaja AK, Sequeira RP. Drug information, misinformation, and disinformation on social media: a content analysis study. J Public Health Pol. 2018;39(3):343–357. doi:10.1057/s41271-018-0131-2
   PubMed Web of Science ®Google Scholar
• El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication Adherence in Older Patients With Dementia: a Systematic Literature Review. J Pharm Prac. 2018;31(3):322–334. doi:10.1177/08971900177105
   PubMedGoogle Scholar
• Tarn DM, Shih K, Tseng C-H, Thomas A, Schwartz JB. Reasons for nonadherence to the direct oral anticoagulant Apixaban: a cross-sectional survey of atrial fibrillation patients. JACC Advances. 2023;2(1):100175. doi:10.1016/j.jacadv.2022.100175
   PubMedGoogle Scholar
• Lau HS, Beuning KS, Postma-Lim E, et al. Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharm World Sci. 1996;18(2):63–68. doi:10.1007/BF00579707
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A Systematic review of the association between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310. doi:10.1016/S0149-2918(01)80109-0
   PubMed Web of Science ®Google Scholar
• Corsonello A, Pedone C, Lattanzio F, et al. Regimen complexity and medication nonadherence in elderly patients. Ther Clin Risk Manag. 2009;5(1):209–216. doi:10.2147/TCRM.S4870
   PubMedGoogle Scholar
• Liu J, Yu Y, Yan S, et al. Risk factors for self-reported medication adherence in community-dwelling older patients with multimorbidity and polypharmacy: a multicenter cross-sectional study. BMC Geriatr. 2023;23(1):75. doi:10.1186/s12877-023-03768-7
   PubMed Web of Science ®Google Scholar
• Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med. 2021;19(1):189. doi:10.1186/s12916-021-02067-5
   PubMed Web of Science ®Google Scholar
• Wetzels GEC, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens. 2004;22(10):1849–1855. doi:10.1097/00004872-200410000-00002
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global report on hypertension. The race against a silent killer. Licence: CC BY-NC-SA 3.0 IGO. WHO; 2023. Available from: https://www.who.int/publications/i/item/9789240081062. Accessed February 26, 2024.
   Google Scholar
• DiMatteo MR, Lepper HS, Croghan TW. Depression Is a Risk Factor for Noncompliance with Medical Treatment. Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence. Arch Intern Med. 2000;160(14):2101–2107. doi:10.1001/archinte.160.14.2101
   PubMed Web of Science ®Google Scholar
• Sundborn LT, Bingefors K. The influence of symptoms of anxiety and depression on medication nonadherence and its causes: a population based survey of prescription drug users in Sweden. Patient Prefer Adherence. 2013;7:805–811. doi:10.2147/PPA.S50055
   PubMed Web of Science ®Google Scholar
• Piette JD, Heisler M, Krein S, Kerr EA. The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med. 2005;165(15):1749–1755. doi:10.1001/archinte.165.15.1749
   PubMed Web of Science ®Google Scholar
• Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients beliefs and preferences regarding doctors’ medication recommendations. J Gen Intern Med. 2008;23(3):236–241. doi:10.1007/s11606-007-0470-3
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;(11):CD000011. doi:10.1002/14651858.CD000011.pub4
   PubMed Web of Science ®Google Scholar
• Haskard Zolnierek KB, DiMatteo MR. Physician Communication and Patient Adherence to Treatment: a Meta-analysis. Med Care. 2009;47(8):826–834.36. doi:10.1097/MLR.0b013e31819a5acc
   PubMed Web of Science ®Google Scholar
• Maniaci MJ, Heckmann MG, Dawson NL. Functional health literacy and understanding of medications in discharge. Mayo Clinc Proc. 2008;83(5):554–558. doi:10.4065/83.5.554
   PubMed Web of Science ®Google Scholar
• Madrid AH, Potpara TS, Dagres N, et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. EP Europace. 2016;18(3):463–467. doi:10.1093/europace/euv448
   PubMed Web of Science ®Google Scholar
• Cao Y, Feng -Y-Y, Du W, et al. Non-persistence to oral anticoagulation therapy in elderly patients with non-valvular atrial fibrillation. Patient Preference Adherence. 2023;17:3185–3194. doi:10.2147/PPA.S435592
   PubMed Web of Science ®Google Scholar
• Leventhal H, Cameron L. Behavioural theories and the problem of compliance. Patient Educ Couns. 1987;10(2):117–138. doi:10.1016/0738-3991(87)90093-0
   Web of Science ®Google Scholar
• Horne R, Weinman J, Barber N, Elliot R, Morgan M Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Delivery and Organisation R & D (NCCSDO). NCCSDO; 2005. Available from: https://www.ahpo.net/assets/NCCSDO%20Compliance%202005.pdf. Accessed January, 2024.
   Google Scholar
• European Medicines Agency. Report of pharmacovigilance tasks from EU Member States and the European Medicines Agency (EMA), 2019–2022. EMA/142695/2023; 2023.
   Google Scholar
• European Innovation Partnership on Active and Healthy Ageing. Adherence to medical plans for older people. European Commission; 2021. Available from: http://chrodis.eu/wp-content/uploads/2015/06/EIP-on-AHA-Infographic-Adherence-to-medical-plans.pdf. Accessed February 26, 2024.
   Google Scholar
• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide Epidemiology of Atrial Fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847. doi:10.1161/CIRCULATIONAHA.113.005119
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988. doi:10.1161/01.STR.22.8.983
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–162. doi:10.1016/S0140-6736(14)61774-8
   PubMed Web of Science ®Google Scholar
• Ding M, Ebeling M, Ziegler L, Wennberg A, Modig K. Time trends in atrial fibrillation-related stroke during 2001–2020 in Sweden: a nationwide, observational study. The Lancet Regional Health. 2023;28:100596. doi:10.1016/j.lanepe.2023.100596
   Google Scholar
• Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–953. doi:10.1093/eurheartj/ehi825
   PubMed Web of Science ®Google Scholar
• Lane DA, Skjøth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017;6(5):e005155. doi:10.1161/JAHA.116.005155
   PubMed Web of Science ®Google Scholar
• Lehto M, Haukka J, Aro A, et al. Comprehensive nationwide incidence and prevalence trends of atrial fibrillation in Finland. Open Heart. 2022;9(2):e002140. doi:10.1136/openhrt-2022-002140
   PubMed Web of Science ®Google Scholar
• Savickas V, Stewart AJ, Rees-Roberts M, et al. Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: a cross-sectional feasibility study. PLoS Med. 2020;17(7):e1003197. doi:10.1371/journal.pmed.1003197
   PubMed Web of Science ®Google Scholar
• Savickas V, Stewart AJ, Mathie A, et al. Screening for atrial fibrillation in care homes using pulse palpation and the AliveCor Kardia Mobile device: a comparative cross-sectional pilot study. Int J Clin Pharm. 2023;46(2):529–535. doi:10.1007/s11096-023-01672-z
   PubMed Web of Science ®Google Scholar
• Ritchie LA, Harrison SL, Penson PE, et al. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018. Age Ageing. 2022;51(12):1–10. doi:10.1093/ageing/afac252
   Web of Science ®Google Scholar
• Alcusky M, Lapane KL. Treatment of atrial fibrillation in nursing homes: a place for direct acting oral anticoagulants? J Nurs Home Res Sci. 2018;4:15–19.
   PubMedGoogle Scholar
• Reardon G, Nelson WW, Patel AA, Philpot T, Neidecker M. Prevalence of Atrial Fibrillation in US Nursing Homes: Results from the National Nursing Home Survey, 1985–2004. J Am Med Dir Assoc. 2012;13(6):529–534. doi:10.1016/j.jamda.2012.03.007
   PubMed Web of Science ®Google Scholar
• Kruger K, Sandli M, Geitung J-T, Eide GE, Grimsmo A. Atrial fibrillation and heart failure in seven nursing homes. J Nurs Educ Pract. 2012;2(4):22–32. doi:10.5430/jnep.v2n4p22
   Google Scholar
• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. doi:10.1177/1747493019897870
   PubMed Web of Science ®Google Scholar
• Sagris D, Lip GYH. Atrial fibrillation, a contemporary sign of multimorbidity and irregular social inequity. Lancet Reg Health Eur. 2022;17:100395. doi:10.1016/j.lanepe.2022.100395
   PubMedGoogle Scholar
• Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141(6):757–763. doi:10.1111/j.1365-2141.2008.07119.x
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Aguilar MI, Hart RG. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;3:CD001927. doi:10.1002/14651858.CD001927.pub2
   PubMedGoogle Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi:10.7326/0003-4819-146-12-200706190-00007
   PubMed Web of Science ®Google Scholar
• Katsanos AH, Kamel H, Healey JS, Hart RG. Stroke prevention in Atrial Fibrillation. Circulation. 2020;142(24):2371–2388. doi:10.1161/CIRCULATIONAHA.120.049768
   PubMed Web of Science ®Google Scholar
• Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335540:546.
   Google Scholar
• National institute for Health and care Excellence (NICE)(2013) CG161. Falls in older people assessing risk and prevention; 2013. Available from https://www.nice.org.uk/guidance/cg161. Assessed January 13, 2024.
   Google Scholar
• Jansen S, Frewen J, Finucane C, de Rooji SE, van der Velde N, Kenny R-A. AF is associated with self-reported syncope and falls in a general population cohort. Age Ageing. 2015;44(4):598–603. doi:10.1093/ageing/afv017
   PubMed Web of Science ®Google Scholar
• Montero-Odasso M, van der Velde N, Martin FC, et al. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51(9):afac205. doi:10.1093/ageing/afad199
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645. doi:10.1016/j.amjmed.2009.11.025
   PubMed Web of Science ®Google Scholar
• Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Int J Stroke. 2011;6(1):42. doi:10.1093/ageing/afr097
   PubMedGoogle Scholar
• Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019;132(7):847–855. doi:10.1016/j.amjmed.2019.01.025
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Pieper K, et al. Outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) II investigators. Frequency and outcomes of reduced non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018;7(4):e007633. doi:10.1161/JAHA.117.007633
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Atrial fibrillation: diagnosis and management: NG196; 2021. Available from: https://www.nice.org.uk/guidance/ng196. Accessed January 31, 2024.
   Google Scholar
• Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–685. doi:10.1001/archinte.159.7.677
   PubMedGoogle Scholar
• Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161(2):241–246. doi:10.1016/j.ahj.2010.11.002
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701–1707. doi:10.1056/NEJM198812293192604
   PubMed Web of Science ®Google Scholar
• Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract. 2006;60(3):258–264. doi:10.1111/j.1368-5031.2006.00790.x
   PubMed Web of Science ®Google Scholar
• Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–2696. doi:10.1161/CIRCULATIONAHA.106.653048
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press; 2022.
   Google Scholar
• Salmasi S, Adelakun A, Safari A, et al. Satisfaction with oral anticoagulants among patients with atrial fibrillation: a Prospective Observational Study. CJC Open. 2021;3(11):1347–1356. doi:10.1016/j.cjco.2021.06.015
   PubMedGoogle Scholar
• Neidecker M, Patel AA, Nelson WW, Reardon G. Use of warfarin in long-term care: a systematic review. BMC Geriatr. 2012;12(1):14. doi:10.1186/1471-2318-12-14
   PubMedGoogle Scholar
• Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119–126. doi:10.1136/heartjnl-2019-315307
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1138–1151. doi:10.1056/NEJMoa0905561
   Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. External reviewers. 2021 European Heart Rhythm Association practical guide on the use on non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23:1612–1676. doi:10.1093/europace/euab065
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. Curr Med Res Opin. 2018;34(7):1285–1292. doi:10.1080/03007995.2018.1428543
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–1678. doi:10.1093/europace/euw295
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76. doi:10.1016/j.jacc.2014.03.022
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747. doi:10.1093/eurheartj/ehs253
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–140. doi:10.1016/j.ahj.2017.08.011
   PubMed Web of Science ®Google Scholar
• Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. EP Europace. 2022;24(6):887–898. doi:10.1093/europace/euab303
   PubMed Web of Science ®Google Scholar
• Mitchell A, Elmasry Y, van Poelgeest E, Welsh TJ. Anticoagulant use in older persons at risk for falls: therapeutic dilemmas-a clinical review. Eur Geriatr Med. 2023;14(4):683–696. doi:10.1007/s41999-023-00811-z
   PubMed Web of Science ®Google Scholar
• Hanon O, Vidal J-S, Le Heuzey J-Y, et al. Oral anticoagulant use in the octogenarian European patients with atrial fibrillation: a subanalysis of PREFER in AF. Int J Cardiol. 2017;232:98–104. doi:10.1016/j.ijcard.2017.01.046
   PubMed Web of Science ®Google Scholar
• Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014;111(3):465–473. doi:10.1160/TH13-05-0424
   PubMed Web of Science ®Google Scholar
• Lowen PS, Ji AT, Kapanen A, McClean A. Patient values and preferences for antithrombotic therapy in atrial fibrillation. Thromb Haemost. 2017;117(6):1007–1022. doi:10.1160/TH16-10-0787
   PubMed Web of Science ®Google Scholar
• Sanghai S, Wong C, Wang Z, et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF Study. J Am Heart Assoc. 2020;9(6):e014108. doi:10.1161/JAHA.119.014108
   PubMed Web of Science ®Google Scholar
• Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation. A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504. doi:10.1111/jth.12845
   PubMed Web of Science ®Google Scholar
• Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015;35(5):1056–1065. doi:10.1161/ATVBAHA.115.303397
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167(6):810–817. doi:10.1016/j.ahj.2014.03.023
   PubMed Web of Science ®Google Scholar
• Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236. doi:10.1186/s12872-017-0671-6
   PubMed Web of Science ®Google Scholar
• Cross AJ, Elliot RA, Petrie K, Kuruvilla L, George J. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst Rev. 2020;5(5):CD012419. doi:10.1002/14651858.CD012419.pub2
   PubMedGoogle Scholar
• Livingstone CR, Pugh ALG, Winn S, Williamson VK. Developing community pharmacy services wanted by local people: information and advice about prescription medicines. Int J Pharmacy Pract. 1996;4(2):94–102. doi:10.1111/j.2042-7174.1996.tb00849.x
   Google Scholar
• Say RE, Thomson R. The importance of patient preferences in treatment decisions-challenges for doctors. BMJ. 2003;327(7414):542–545. doi:10.1136/bmj.327.7414.542
   PubMedGoogle Scholar
• Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence a qualitative study with general practitioners. BMJ Open. 2018;8(1):e015232. doi:10.1136/bmjopen-2016-015332
   Web of Science ®Google Scholar
• Rathbone AP, Mansoor SM, Krass I, Hamrosi K, Aslani P. Qualitative study to conceptualise a model of interprofessional collaboration between pharmacists and general practitioners to support patients’ adherence to medication. BMJ Open. 2016;16(6):e010488. doi:10.1136/bmjopen-2015-010488
   Google Scholar
• American Society of Health-System Pharmacists. ASHP guidelines on pharmacist-conducted patient education and counselling. Am J Health-Sys Pharm. 1997;54(4):431–434. doi:10.1093/ajhp/54.4.431
   PubMedGoogle Scholar
• Valliant SN, Burbage SC, Pathak S, Urick BY. Pharmacists as accessible health care providers: quantifying the opportunity. J Manag Care Spec Pharm. 2022;28(1):85–90. doi:10.18553/jmcp.2022.28.1.85
   PubMed Web of Science ®Google Scholar
• Tsuyuki RT, Beahm NP, Okada H, Al Hamarneh YN. Pharmacists as accessible primary health care providers: review of the evidence. Canadian Pharmacists J. 2018;151(1):4–5. doi:10.1177/1715163517745517
   Google Scholar
• Ritchie LA, Penson PE, Akpan A, Lip GYH, Lane DA. Integrated care for atrial fibrillation management: the role of the pharmacist. Am J Med. 2022;135(12):1410–1426. doi:10.1016/j.amjmed.2022.07.014
   PubMed Web of Science ®Google Scholar
• Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627–628. doi:10.1038/nrcardio.2017.153
   PubMed Web of Science ®Google Scholar
• Chao T-F, Joung B, Takahashi Y, et al. Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in Atrial Fibrillation: executive summary. Thromb Haemost. 2021;122(1):20–47. doi:10.1055/s-0041-1739411
   PubMedGoogle Scholar
• Gov.UK. Community Pharmacy Contractual Framework for 2019/2020 to 2023/24: supporting delivery for the NHS Long Term Plan; 2019. Available from: https://www.gov.uk/government/publications/community-pharmacy-contractual-framework-2019-to-2024. Accessed February 8, 2024.
   Google Scholar
• National Health Service. Advanced Service Specification – NHS New Medicine Service (NMS); 2021. Available from: https://www.england.nhs.uk/publication/advanced-service-specification-nhs-new-medicine-service-nms/. Accessed October 8, 2024.
   Google Scholar
• National Health Service. NHS Community Pharmacy New Medicine Service (NMS) Expansion Pilot: inclusion of Depression as a Therapeutic Area and Revised Service Delivery Model. NHS England; 2022. Available from: https://www.nhsbsa.nhs.uk/sites/default/files/2022-09/NMS%20Expansion%20Pilot%20SLA-ServiceSpec%20FINAL%20v1.0.pdf. Accessed February 8, 2024.
   Google Scholar
• Hindi AMK, Schafheutle EI, Jacobs S. Patient and public perspectives of community pharmacies in the United Kingdom: a Systematic review. Health Expect. 2018;21(2):409–428. doi:10.1111/hex.12639
   PubMed Web of Science ®Google Scholar
• Chartrand M, Lalonde L, Cantin A, et al. Anticoagulation management services in community pharmacy: feasibility of implementing a quality improvement programme through a practice-based research network. J Clin Pharm Ther. 2018;43(6):877–887. doi:10.1111/jcpt.12745
   PubMed Web of Science ®Google Scholar
• Ingram SJ, Kirkdale CL, Williams S, et al. Moving of anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and Hove community pharmacy service. BMC Health Ser Res. 2018;18(1):91. doi:10.1186/s12913-018-2901-8
   PubMedGoogle Scholar
• Harper P, McMichael I, Griffiths D, Harper J, Hill C. The community-based anticoagulation management service achieves a consistently high standard of anticoagulant care. N Z Med J. 2015;128(1422):31–41.
   PubMedGoogle Scholar
• Rossiter J, Soor G, Telner D, Aliarzadeh B, Lake J. A pharmacist-led point-of-care INR clinic: optimizing care in a family health setting. Int J Family Med. 2013;2013:691454. doi:10.1155/2013/691454
   PubMedGoogle Scholar
• Sharma R, Hasan SS, Gilkar IA, Hussain WF, Conway BR, Ghori MU. Pharmacist-Led interventions in optimising the use of oral anticoagulants in atrial fibrillation patients in the general practice in England: a retrospective observational study. BJGP Open. 2023;0113. doi:10.3399/BJGPO.2023.0113
   Google Scholar
• Ashjian E, Kurtz B, Renner E, Yeshe R, Barnes GD. Evaluation of a pharmacist-led outpatient direct oral anticoagulant service. AJHP. 2017;74(7):483–489. doi:10.2146/ajhp151026
   Google Scholar
• Grzesk G, Janiszewska E, Malinowski B, Kubica A, Wicinski M. Adherence in patients with atrial fibrillation treated with dabigatran. Kardiol Pol. 2018;76(11):1562–1563. doi:10.5603/KP.a2018.0194
   PubMed Web of Science ®Google Scholar
• Merks P, Cameron JD, Balcerzak M, et al. Evaluation of a pharmacist-led intervention to improve medication adherence in patients initiating dabigatran treatment: a comparison with standard pharmacy practice in Poland. BMC Primary Care. 2022;23(1):210. doi:10.1186/s12875-022-01821-9
   PubMedGoogle Scholar
• Aidit S, Soh YC, Yap CS, et al. Effect of standardized warfarin treatment protocol on anticoagulant effect: comparison of a warfarin medication therapy adherence clinic with usual medical care. Front Pharmacol. 2017;8:637.10.3389. doi:10.3389/fphar.2017.00637
   PubMed Web of Science ®Google Scholar
• Lee T, Davis E, Kelly J. Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature. Integr Pharm Res Prac. 2016;5:53–63. doi:10.2147/IPRP.S93312
   PubMedGoogle Scholar
• Phelps E, Delate T, Witt DM, Shaw PB, McCool KH, Clark NP. Effect of increased time in therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. Thromb Res. 2018;163:54–59. doi:10.1016/j.thromres.2018.01.024
   PubMed Web of Science ®Google Scholar
• Marcatto LR, Sacilotto L, Tavares LC, et al. Pharmaceutical care increases time in therapeutic range of patients with poor quality of anticoagulation with warfarin. Front Pharmacol. 2018;9:1052. doi:10.3389/fphar.2018.01052
   PubMed Web of Science ®Google Scholar
• Proietti M, Lane DA. The compelling issue of nonvitamin K antagonist oral anticoagulant adherence in atrial fibrillation patients: a systematic need for new strategies. Thromb Haemost. 2020;120(3):369–371. doi:10.1055/s-0039-1697954
   PubMed Web of Science ®Google Scholar
• NHS England. Electronic repeat dispensing (eRD); 2023. Available from: https://www.england.nhs.uk/long-read/electronic-repeat-dispensing-erd/. Accessed February 8, 2024.
   Google Scholar
• Kelly DV, Young S, Philips L, Clark D. Patient attitudes regarding the role of the pharmacist and interest in expanded pharmacist services. Can Pharm J. 2014;147(4):239–247. doi:10.1177/1715163514535731
   Google Scholar
• Blalock SJ, Roberts AW, Lauffenburger JC, Thompson T, O’Connor SK. The effect of community pharmacy-based interventions on patient health outcomes: a systematic review. Med Care Res Rev. 2013;70(3):235–266. doi:10.1177/10775587124592
   PubMed Web of Science ®Google Scholar
• Al-Khatib A, Andreski M, Pudlo A, Doucette WR. An evaluation of community pharmacies’ actions under value-based payment. JAPHA. 2020;60(6):899–905. doi:10.1016/j.japh.2020.06.014
   Google Scholar